Bispecific Antibodies Market By Applications (Infectious Diseases, Bacterial Infections, Viral Infections, Cancer Diagnostic, Signaling Pathways, Tumor Angiogenesis, Gene Therapy), By Product (Quadromas, Chemical heteroconjugates), Industry Trends, Estimation & Forecast, 2017 - 2025

July 2018

 Pages: 182

 ERC 7597


Bispecific antibodies market is expected to grow with a CAGR of XX% during the forecast period of 2018 to 2025.

Bispecific antibodies (BsAbs) or bispecific immunoglobulins, are the artificially constructed protiens, which can bind to two different antigen sites at one time. The market for bispecific antibodies is still in its nascent stage and has not witnessed a significant penetration within the healthcare industry till yet. Removab® was the first trifunctional antibody which was approved by the European Medicines Agency for treating malignant ascites in 2009. However, its marketing authorization was withdrawn in the EU at the request of Neovil Biotech GmbH in 2017. In the current scenario, around 60 drugs are being tested in preclinical trials and 30 in clinical trials, out of which nearly 67% of these are intented for the cancer treatment.

Constantly increasing cases of Acute Lymphocytic Leukemia (ALL) is emerging out as the major driving factor for the market growth. The bispecific blinatumomab molecule, which was developed by using diabody technology is now being extensively used for curing acute lymphocytic leukemia (ALL). Moreover, these bispecific antibodies have been also found highly efficient in the treatment of various types of cancer such as breast cancer, cervical cancer and lung cancer. As per the data revealed by American Cancer Society, America is estimated to witness 5,960 new cases of ALL, comprising of 3,290 male cases and 2,670 female cases, in the current year. However, certain challenges such as stringent regulations, coupled with high cost involved in research and development activities of these drugs are expected to hinder the market growth.

On the other hand, continuous R&D and successful approvals of advanced bispecific antibodies is anticipated to generate lucrative opportunities for the leading manufacturers. Ozoralizumab, a nanobody, has recently completed its phase-2 clinical trial and its administration has shown a significant improvement in the patients suffering with rheumatoid arthritis (RA). Collaboration and product launch have emerged out as some of the most adopted strategies among the major market players in order to expand their businesses and strengthen their foothold within the market. In April 2018, Zymeworks and Celgene have gone through a collaboration owing to the intensification of research & development, and commercialization of bispecific antibody therapeutics. This collaboration has enabled Celgene to research and develop multiple bispecific antibodies based on Zymeworks’ Azymetric™ platform.

The report provides detailed qualitative and quantitative analysis of the bispecific antibodies market. Market size and forecast has been provided for the period - (2018 - 2025), for the segments namely product and application in each of the major regions.

Bispecific Antibodies Market Player Analysis -

The report presents detailed analysis of major players operating in bispecific antibodies market. Few of them include AbbVie, Janssen Biotech, Amgen, Inc., Bayer AG, Immunocore Limited, Celgene, Ganymed Pharmaceuticals, OncoMed Pharmaceuticals, Paktis Antibody Services GmbH, Fabion Pharmaceuticals, Merck & Co., Inc., Dow Pharmaceutical Solutions, ImmunGene, Inc., Novartis AG, Pfizer, Inc., and F. Hoffmann-La Roche AG. A detailed coverage on these market players with information on their revenue from bispecific antibodies business, market share, gross margin and their growth strategies have been provided in the report.

Market Segmentation

Bispecific antibodies market is segmented on the basis application, product and geography. By product, the market is segmented into quadromas, chemical heteroconjugates and others. On the basis of application, the market is categorized as infectious diseases, bacterial infections, viral infections, and cancer diagnostic Geographical coverage has been provided for each of the major regions including North America, Europe, Asia-Pacific, South America and Rest of the World.

Bispecific Antibodies Market Segmentation

By Applications
• Infectious Diseases
• Bacterial Infections
• Viral Infections
• Cancer Diagnostic
• Signaling Pathways
• Tumor Angiogenesis
• Gene Therapy

By Product
• Quadromas
• Chemical heteroconjugates
• Others

By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o France
o Germany
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o China
o Japan
o India
o Korea
o Rest of APAC
• South America
o Brazil
o Rest of South America
• Rest of the World
o Middle East
o Africa

Bispecific Antibodies Market Key Players

• AbbVie
• Janssen Biotech
• Amgen, Inc.
• Bayer AG
• Immunocore Limited
• Celgene
• Ganymed Pharmaceuticals
• OncoMed Pharmaceuticals
• Paktis Antibody Services GmbH
• Fabion Pharmaceutical
• Merck & Co., Inc.
• Dow Pharmaceutical Solutions
• ImmunGene, Inc., Novartis AG,
• Pfizer, Inc.
• F. Hoffmann-La Roche AG

Please fill in the form below to Request for Customized Report
Your personal details are safe and secured with us. Privacy Policy

To request sample copy of this report, please complete the form below verified and secure

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Your personal details are safe and secured with us. Privacy Policy

    What Information does this report contain?

    • What was the market size of the Bispecific Antibodies Market in 2017 and the expected market size by 2025, along with the growth rate?
    • An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
    • Which are the largest revenue generating products, services or regions and their comparative growth rate?
    • Which technology is in trend and how would it evolve during the forecast period (2017 - 2025)?
    • Which are the leading companies in the Bispecific Antibodies Market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?

Purchase Options

Offers & Discounts

  • Chapter purchase
  • Historical market data
  • Country level data breakdown
  • Free customization*
  • Discounts for first time
  • Special pricing for
              non-business entities


  • We offer 20% free customization on every purchase.

Get in touch!